Skip to main
ELMD

Electromed (ELMD) Stock Forecast & Price Target

Electromed (ELMD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Electromed Inc. reported a substantial growth in homecare revenue, which increased by 14.8%, reaching $14.1 million, driven by enhanced sales rep productivity and effective demand generation strategies. The company demonstrated significant expansion in its market presence, with notable increases in distributor sales by 41% and hospital sales by 52%, indicating robust demand for its airway clearance products. Furthermore, the rise in SG&A expenses by 17.2% reflects Electromed's strategic investments in scaling its operations, positioning the company well for continued growth in the homecare and acute care sectors.

Bears say

Electromed Inc. faces a challenging financial outlook due to several fundamental issues, including margin compression, increasing competitive pressures, and diminished sales representative productivity, which may hinder revenue growth. Additionally, potential delays in the company's growth drivers for Pain Management and Wound Care could further adversely impact expected growth rates and profit margins. The significant decline in stock value from a recent peak of $35.43 to approximately $18 underscores investor concerns about the company's ability to navigate these obstacles effectively.

Electromed (ELMD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Electromed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Electromed (ELMD) Forecast

Analysts have given Electromed (ELMD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Electromed (ELMD) has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Electromed (ELMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.